Microwave ablation and artery occlusion for treating secondary hypersplenism
Official title: A Single-Arm Clinical Study Evaluating Microwave Ablation of the Spleen Combined With Splenic Artery Occlusion for Secondary Hypersplenism Treatment
Run by Tianjin Medical University Cancer Institute and Hospital · NCT06292715 · Data updated 2026-11-12
This study is testing a new treatment that combines microwave heat and blocking a blood vessel to help people with severe hypersplenism related to cirrhosis who haven't found relief with standard therapies.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 35 (estimated) |
| Sponsor | Tianjin Medical University Cancer Institute and Hospital Academic / other |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Status | Recruiting |
| Started | January 20, 2024 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT06292715 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 with severe hypersplenism secondary to cirrhosis and poor response to previous treatments.
✕Probably not a fit
Patients with coagulopathy, severe hypertension, or other significant comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of a combined treatment approach involving microwave ablation of the spleen and splenic artery occlusion for patients suffering from secondary hypersplenism. It is an open-label, single-arm, single-center trial conducted at Tianjin Medical University Cancer Institute and Hospital. The study aims to provide a new therapeutic option for patients who have not responded well to conventional treatments for severe hypersplenism associated with cirrhosis.
Why it matters
Potential benefit: If successful, this treatment could significantly improve blood cell counts and overall health for patients with severe secondary hypersplenism.
How similar studies have gone: While this approach is innovative, there is limited data on similar combined interventions specifically for secondary hypersplenism.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. written informed consent signed prior to enrolment 2. age \> 18 years, both sexes 3.Patients with severe hypersplenism secondary to cirrhosis with clinical diagnosis, White blood cells \<3×109/L, and/or platelet \<50×109/L 4.Patients who have been repeatedly given drugs to raise white blood cells and platelets in clinical practice have poor effect 5.Mental problems such as clinical symptoms or anxiety in patients require interventional treatment for hypersplenism Exclusion Criteria: * Patients with any of the following are not eligible for enrollment in this study 1. Coagulopathy or other blood disorders 2. Recent use of anticoagulant drugs 3. Severe hypertension and cardiac insufficiency 4. Bone marrow aspiration results showed bone marrow suppression 5. Combined with other spleen malignant diseases 6. Severe skin infection at the puncture site 7. Participated in other clinical studies within 2 months prior to the start of the study 8. Patient or his/her authorized person is unwilling to sign a written informed consent form or unwilling to comply with the study protocol
Where it's running
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Principal investigator: WEI LU, PhD — Tianjin Cancer Hospital Airport Hospital
- Study coordinator: WEI LU, PhD
- Email: luwei1966@126.com
- Phone: 13820476460
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
Biomarker testing to predict treatment response and recurrence in liver cancer
This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.
-
Phase II test of SHR-A1811 for ultra-low HER2 advanced breast cancer
This phase II trial tests SHR-A1811 in women with advanced breast cancer and ultra-low HER2 expression who have had 1-2 prior therapies.
-
Risk-stratified management of inavolisib-induced hyperglycemia in breast cancer patients
This observational study tests whether using a pre-treatment risk-stratified plan to manage high blood sugar from inavolisib helps patients stay on therapy.
-
Stereotactic body radiation therapy for spinal metastases with epidural compression
This study tests whether SBRT can safely help adults with spinal metastases that compress the spinal cord see if the treatment works in reducing issues from their cancer.
-
Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC
This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.